William D. Turner - Dec 3, 2025 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Signature
/s/ Joseph R. Young, Attorney-in-Fact
Stock symbol
VERA
Transactions as of
Dec 3, 2025
Transactions value $
-$244,700
Form type
4
Date filed
12/4/2025, 04:05 PM
Previous filing
Feb 20, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Turner William D. Chief Regulatory Officer C/O VERA THERAPEUTICS, INC., 2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE /s/ Joseph R. Young, Attorney-in-Fact 2025-12-04 0001819688

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERA Class A Common Stock Options Exercise $155K +10K +44.44% $15.53 32.5K Dec 3, 2025 Direct
transaction VERA Class A Common Stock Sale -$400K -10K -30.77% $40.00 22.5K Dec 3, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERA Stock Option (right to buy) Options Exercise $0 -10K -3.64% $0.00 265K Dec 3, 2025 Class A Common Stock 10K $15.53 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 20, 2025.
F2 1/4 of the shares subject to the option vested on January 5, 2025, and 1/48 of the shares vest monthly thereafter, subject to continuous service of the Reporting Person through each vesting date.